These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 31832993)

  • 81. Antiandrogen and hormonal treatment of acne.
    Shaw JC
    Dermatol Clin; 1996 Oct; 14(4):803-11. PubMed ID: 9238337
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Hormonal assessment in a woman with acne and alopecia].
    Faure M; Drapier-Faure E
    Rev Fr Gynecol Obstet; 1992 Jun; 87(6):331-4. PubMed ID: 1385888
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Brown J; Farquhar C; Lee O; Toomath R; Jepson RG
    Cochrane Database Syst Rev; 2009 Apr; (2):CD000194. PubMed ID: 19370553
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Finasteride Topical Delivery Systems for Androgenetic Alopecia.
    Khan MZU; Khan SA; Ubaid M; Shah A; Kousar R; Murtaza G
    Curr Drug Deliv; 2018; 15(8):1100-1111. PubMed ID: 29366416
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future.
    Wipf A; Boysen N; Hordinsky MK; Dando EE; Sadick N; Farah RS
    J Cosmet Laser Ther; 2019 Aug; 21(5):247-254. PubMed ID: 30300013
    [No Abstract]   [Full Text] [Related]  

  • 86. Frontal edema due to mesotherapy for androgenetic alopecia: A case series.
    Melo DF; Saceda-Corralo D; Tosti A; Weffort F; Carla Jorge M; de Barros CC; de Melo Carvalho R; Starace M
    Dermatol Ther; 2022 Feb; 35(2):e15247. PubMed ID: 34877759
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Androgen antagonists in androgen target tissues.
    Tindall DJ; Chang CH; Lobl TJ; Cunningham GR
    Pharmacol Ther; 1984; 24(3):367-400. PubMed ID: 6205409
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review.
    Wang C; Du Y; Bi L; Lin X; Zhao M; Fan W
    Clin Cosmet Investig Dermatol; 2023; 16():603-612. PubMed ID: 36923692
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Anti-androgens. Their use in dermatology].
    Montero ED; Arevalo A; Michelotti M
    Med Cutan Ibero Lat Am; 1981; 9(4):275-84. PubMed ID: 6456390
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro.
    Rosette C; Agan FJ; Mazzetti A; Moro L; Gerloni M
    J Drugs Dermatol; 2019 May; 18(5):412-418. PubMed ID: 31141847
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hormonal therapy in dermatology.
    Shaw JC
    Dermatol Clin; 2001 Jan; 19(1):169-78, ix. PubMed ID: 11155581
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit?
    Singh S; Patil A; Kianfar N; Waśkiel-Burnat A; Rudnicka L; Sinclair R; Goldust M
    Clin Exp Dermatol; 2022 Nov; 47(11):1951-1955. PubMed ID: 35881665
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia.
    Melo DF; de Mattos Barreto T; Plata GT; Araujo LR; Tortelly VD
    J Cosmet Dermatol; 2020 Jan; 19(1):75-77. PubMed ID: 31066492
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-blinded, active-controlled trial.
    Rokni GR; Mohammadnezhad F; Saeedi M; Shadi S; Sharma A; Sandhu S; Gupta A; Goldust M
    J Cosmet Dermatol; 2021 Nov; 20(11):3580-3585. PubMed ID: 34648685
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review.
    Gupta AK; Mays RR; Versteeg SG; Shear NH; Piguet V; Piraccini BM
    Clin Drug Investig; 2019 Mar; 39(3):233-239. PubMed ID: 30652260
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride.
    Chandrashekar BS; Nandhini T; Vasanth V; Sriram R; Navale S
    Indian Dermatol Online J; 2015; 6(1):17-20. PubMed ID: 25657911
    [TBL] [Abstract][Full Text] [Related]  

  • 97. 5 alpha-reductase and finasteride in pattern alopecia and acne.
    Burkhart CG; Burkhart CN
    J Drugs Dermatol; 2004; 3(4):363-4. PubMed ID: 15303779
    [No Abstract]   [Full Text] [Related]  

  • 98. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia.
    Dhurat R; Chitallia J; May TW; Jayaraaman AM; Madhukara J; Anandan S; Vaidya P; Klenk A
    Skin Pharmacol Physiol; 2017; 30(6):298-305. PubMed ID: 29055953
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris.
    Stotland M; Shalita AR; Kissling RF
    Am J Clin Dermatol; 2009; 10(4):221-7. PubMed ID: 19489655
    [TBL] [Abstract][Full Text] [Related]  

  • 100. New investigational drugs for androgenetic alopecia.
    Valente Duarte de Sousa IC; Tosti A
    Expert Opin Investig Drugs; 2013 May; 22(5):573-89. PubMed ID: 23550739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.